Towa Pharmaceutical Co (4553) Price & Analysis

Compare

0 Followers

4553 Stock Chart & Stats

Day’s Range― - ―

52-Week Range¥2,298.00 - ¥3,395.00

Previous CloseN/A

Volume116.60K

Average Volume (3M)117.39K

Market Cap

¥124.22B

Enterprise Value¥327.50B

Total Cash (Recent Filing)¥29.25B

Total Debt (Recent Filing)¥223.48B

Price to Earnings (P/E)6.4

Beta0.64

Next Earnings

May 15, 2025

EPS Estimate

113.89

Last Dividend Ex-Date

Mar 28, 2025

Dividend Yield2.73%

Share Statistics

EPS (TTM)391.66

Shares Outstanding51,516,000

10 Day Avg. Volume97,210

30 Day Avg. Volume117,389

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥3,020.42

Price Target Upside17.89% Upside

Rating ConsensusHold

Number of Analyst Covering1

---

Towa Pharmaceutical Co News

PremiumCompany Announcements

Towa Pharmaceutical Enhances Internal Control System

1M ago

PremiumCompany Announcements

Towa Pharmaceutical Co. Updates Financial Results and Consolidates Subsidiaries

2M ago

PremiumCompany Announcements

Towa Pharmaceutical’s Robust Financial Growth in 2024

2M ago

PremiumCompany Announcements

Towa Pharmaceutical Revises Dividend Forecasts Upward

2M ago

PremiumPre-Earnings

TWAPF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

2M ago

PremiumCompany Announcements

Towa Pharmaceutical Unveils 2024 Integrated Report and Strategic Plan

4M ago

PremiumCompany Announcements

Towa Pharmaceutical Reports Strong Sales but Decline in Profit

5M ago

PremiumPre-Earnings

TWAPF Earnings this Week: How Will it Perform?

5M ago

See All JP:4553 News

---

Financials

Quarterly

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

7.16%

Mutual Funds

― Other Institutional Investors

90.26% Public Companies and

Individual Investors

Detailed Ownership Overview >

4553 FAQ

What was Towa Pharmaceutical Co ’s price range in the past 12 months?

Towa Pharmaceutical Co lowest stock price was ¥2298.00 and its highest was ¥3395.00 in the past 12 months.

What is Towa Pharmaceutical Co ’s market cap?

Towa Pharmaceutical Co ’s market cap is ¥124.22B.

When is Towa Pharmaceutical Co ’s upcoming earnings report date?

Towa Pharmaceutical Co ’s upcoming earnings report date is May 15, 2025 which is in 22 days.

How were Towa Pharmaceutical Co ’s earnings last quarter?

Towa Pharmaceutical Co released its earnings results on Feb 13, 2025. The company reported ¥163.93 earnings per share for the quarter, beating the consensus estimate of ¥57.659 by ¥106.271.

Is Towa Pharmaceutical Co overvalued?

According to Wall Street analysts Towa Pharmaceutical Co ’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Towa Pharmaceutical Co pay dividends?

Towa Pharmaceutical Co pays a Annually dividend of ¥30 which represents an annual dividend yield of 2.73%. See more information on Towa Pharmaceutical Co dividends here

What is Towa Pharmaceutical Co ’s EPS estimate?

Towa Pharmaceutical Co ’s EPS estimate is 113.89.

How many shares outstanding does Towa Pharmaceutical Co have?

Towa Pharmaceutical Co has 51,516,000 shares outstanding.

What happened to Towa Pharmaceutical Co ’s price movement after its last earnings report?

Towa Pharmaceutical Co reported an EPS of ¥163.93 in its last earnings report, beating expectations of ¥57.659. Following the earnings report the stock price went up 2.399%.

Which hedge fund is a major shareholder of Towa Pharmaceutical Co ?

Currently, no hedge funds are holding shares in JP:4553

---

Company Description

Towa Pharmaceutical Co

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.

---

4553 Stock 12 Month Forecast

Average Price Target

¥3,020.42

▲(17.89% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1724":"¥1,724","3041":"¥3,041","2053.25":"¥2,053.3","2382.5":"¥2,382.5","2711.75":"¥2,711.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3020.419739106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥3.02K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3020.419739106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥3.02K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3020.419739106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥3.02K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1724,2053.25,2382.5,2711.75,3041],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2021","6":"Jul<br/>2021","9":"Sep<br/>2021","12":"Feb<br/>2025","25":"Feb<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2971.897,2975.629518392769,2979.3620367855383,2983.0945551783075,2986.827073571077,2990.5595919638463,2994.2921103566155,2998.0246287493846,3001.757147142154,3005.489665534923,3009.2221839276926,3012.954702320462,3016.687220713231,{"y":3020.419739106,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2971.897,2975.629518392769,2979.3620367855383,2983.0945551783075,2986.827073571077,2990.5595919638463,2994.2921103566155,2998.0246287493846,3001.757147142154,3005.489665534923,3009.2221839276926,3012.954702320462,3016.687220713231,{"y":3020.419739106,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2971.897,2975.629518392769,2979.3620367855383,2983.0945551783075,2986.827073571077,2990.5595919638463,2994.2921103566155,2998.0246287493846,3001.757147142154,3005.489665534923,3009.2221839276926,3012.954702320462,3016.687220713231,{"y":3020.419739106,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1725.433,"date":1609459200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1878.765,"date":1612137600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1938.294,"date":1614556800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2186.509,"date":1617235200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2058.212,"date":1619827200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2190.149,"date":1622505600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2497.697,"date":1625097600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2625.085,"date":1627776000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2788.869,"date":1630454400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2788.869,"date":1630454400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2707.598,"date":1635724800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3040.897,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2971.897,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >